TITLE:
Efficacy of Plerixafor for Peripheral Stem Cell Mobilisation in Autologous Transplantation: A Single Centre Study
AUTHORS:
Kiran Pura Krishnamurthy, D. V. Ganesha, Girish Badarkhe, Diganta Hazarika, Radheshyam Naik
KEYWORDS:
Plerixafor, Poor Mobilizers, ASCT
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.11 No.8,
August
18,
2020
ABSTRACT: Plerixafor
is a stem cell mobilising agent, and when administered along with G-CSF has
been shown to improve CD34+ stem cell collections in lymphoma and multiple
myeloma patients compared to G-CSF alone. Patients who failed to mobilize 6 cells/kg on Day 1 collection received Plerixafor and G CSF for
further collections. Study population was divided into two groups as plerixafor
yes (PY) who are poor mobilizers and Plerixafor No (PN) who are good
mobilizers. Out of 49 patients, 28 patients were in PY group and 21 patients in
PN group. Median value of apheresis CD34 of day 1 was 1.75 (range 0.258 to
8.52) in PY group and 2.63 (range 1.06 to 6.29) in PN group and that of day 2
was 3.845 (range 0.317 to 13.89) in PY group and 3.18 (range 0.88 to 6.348) in
PN group. Median value of total apheresis CD34 was 8.10 (range 4.33 to 18.66)
in PY group and 7.58 (range 4.06 to 9.8) in PN group. Median day of neutrophil
engraftment was 11.5 (range 9 - 22) in PY group and 11 (range 9 - 36) in PN
group whereas median day of platelet engraftment was 14 (range 9 - 98) in PY
group and 13 (range 11 - 98) in PN group. It can be concluded that the use of
plerixafor not only enabled poor mobilizers of Lymphoma and Multiple Myeloma to
collect adequate stem cells to proceed to ASCT, but also had early neutrophil
and platelet engraftment which was comparable with good mobilizers.